Baidu
map

Sci Rep:良性前列腺增生生长过程中通过自身抗原识别的补体激活研究

2020-01-16 AlexYang MedSci原创

良性前列腺增生(BPH)的病理生理机制仍旧不清楚。最近,有研究人员利用小鼠模型聚焦了BHP生长过程中的补体激活过程。研究人员从进行了小鼠泌尿生殖窦植入术的小鼠中获取了BPH组织,并通过实时定量RT-PCR、蛋白免疫印迹和免疫组化技术(IHC)分析了小鼠和人类BPH组织中C1q、C3、甘露糖结合凝集素(MBL)、因子B (FB)和C5b-9的局部表达和累积水平,还利用ELISA和IHC分别分析了血清

良性前列腺增生(BPH)的病理生理机制仍旧不清楚。最近,有研究人员利用小鼠模型聚焦了BHP生长过程中的补体激活过程。

研究人员从进行了小鼠泌尿生殖窦植入术的小鼠中获取了BPH组织,并通过实时定量RT-PCR、蛋白免疫印迹和免疫组化技术(IHC)分析了小鼠和人类BPH组织中C1q、C3、甘露糖结合凝集素(MBL)、因子B (FB)和C5b-9的局部表达和累积水平,还利用ELISA和IHC分别分析了血清IgG水平和组织定位。研究发现,与正常组织相比,C1q、C3、MBL、FB和C5b-9高度集中在小鼠BPH组织中。与之不同,与人类正常组织相比,C3、FB和C5b-9,但不包括C1q和MBL,在人类BPH组织中高度富集。研究人员发现了小鼠BPH组织中IgGd的分散定位。另外,热激蛋白90、膜联单白、α-平滑肌肌动蛋白和β-肌动蛋白是BHP模型中IgG自身抗体识别靶标。

最后,研究人员指出,他们的结果表明了BHP生长过程中补体的激活很可能通过自身抗体经典的激活途径来激发。

原始出处:

Junya Hata, Takeshi Machida, Kanako Matsuoka et al. Complement activation by autoantigen recognition in the growth process of benign prostatic hyperplasia. Sci Rep. 30 Dec 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1810837, encodeId=1a68181083e5b, content=<a href='/topic/show?id=5af886363e5' target=_blank style='color:#2F92EE;'>#自身抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86363, encryptionId=5af886363e5, topicName=自身抗原)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Dec 04 01:02:00 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509700, encodeId=20851509e0063, content=<a href='/topic/show?id=c96f866535c' target=_blank style='color:#2F92EE;'>#良性前列腺增生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86653, encryptionId=c96f866535c, topicName=良性前列腺增生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42f10130242, createdName=刘阔, createdTime=Sat Jan 18 12:02:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592086, encodeId=45cf1592086a8, content=<a href='/topic/show?id=f7b7901238d' target=_blank style='color:#2F92EE;'>#补体激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90123, encryptionId=f7b7901238d, topicName=补体激活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f218082312, createdName=sodoo, createdTime=Sat Jan 18 12:02:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623363, encodeId=38c71623363b9, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Jan 18 12:02:00 CST 2020, time=2020-01-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1810837, encodeId=1a68181083e5b, content=<a href='/topic/show?id=5af886363e5' target=_blank style='color:#2F92EE;'>#自身抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86363, encryptionId=5af886363e5, topicName=自身抗原)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Dec 04 01:02:00 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509700, encodeId=20851509e0063, content=<a href='/topic/show?id=c96f866535c' target=_blank style='color:#2F92EE;'>#良性前列腺增生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86653, encryptionId=c96f866535c, topicName=良性前列腺增生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42f10130242, createdName=刘阔, createdTime=Sat Jan 18 12:02:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592086, encodeId=45cf1592086a8, content=<a href='/topic/show?id=f7b7901238d' target=_blank style='color:#2F92EE;'>#补体激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90123, encryptionId=f7b7901238d, topicName=补体激活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f218082312, createdName=sodoo, createdTime=Sat Jan 18 12:02:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623363, encodeId=38c71623363b9, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Jan 18 12:02:00 CST 2020, time=2020-01-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1810837, encodeId=1a68181083e5b, content=<a href='/topic/show?id=5af886363e5' target=_blank style='color:#2F92EE;'>#自身抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86363, encryptionId=5af886363e5, topicName=自身抗原)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Dec 04 01:02:00 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509700, encodeId=20851509e0063, content=<a href='/topic/show?id=c96f866535c' target=_blank style='color:#2F92EE;'>#良性前列腺增生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86653, encryptionId=c96f866535c, topicName=良性前列腺增生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42f10130242, createdName=刘阔, createdTime=Sat Jan 18 12:02:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592086, encodeId=45cf1592086a8, content=<a href='/topic/show?id=f7b7901238d' target=_blank style='color:#2F92EE;'>#补体激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90123, encryptionId=f7b7901238d, topicName=补体激活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f218082312, createdName=sodoo, createdTime=Sat Jan 18 12:02:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623363, encodeId=38c71623363b9, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Jan 18 12:02:00 CST 2020, time=2020-01-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1810837, encodeId=1a68181083e5b, content=<a href='/topic/show?id=5af886363e5' target=_blank style='color:#2F92EE;'>#自身抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86363, encryptionId=5af886363e5, topicName=自身抗原)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Dec 04 01:02:00 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509700, encodeId=20851509e0063, content=<a href='/topic/show?id=c96f866535c' target=_blank style='color:#2F92EE;'>#良性前列腺增生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86653, encryptionId=c96f866535c, topicName=良性前列腺增生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42f10130242, createdName=刘阔, createdTime=Sat Jan 18 12:02:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592086, encodeId=45cf1592086a8, content=<a href='/topic/show?id=f7b7901238d' target=_blank style='color:#2F92EE;'>#补体激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90123, encryptionId=f7b7901238d, topicName=补体激活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f218082312, createdName=sodoo, createdTime=Sat Jan 18 12:02:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623363, encodeId=38c71623363b9, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Jan 18 12:02:00 CST 2020, time=2020-01-18, status=1, ipAttribution=)]

相关资讯

饱受前列腺增生“折磨”,吃药还是手术?

众所周知,良性前列腺增生症又称良性前列腺肥大症,是中老年男性常见疾病。很多患者认为前列腺增生大是随着年龄的增大出现的正常现象,而且多数是良性病变,没有多大危害,无需治疗,忍一忍就好了。然而,上海市静安中心医院泌尿外科主任周任远强调,“良性不代表不会病变,不会对患者造成严重的后果,前列腺增生是进展性疾病,如果不尽早治疗,病情只会越拖越严重,导致患者尿潴留,尿路感染,膀胱结石,血尿,甚至发展成肾功能衰

前列腺增生患者的福音:经尿道前列腺扩开术解决棘手问题

4月18日,“前列腺扩开术国际医疗交流培训基地”挂牌仪式在上海交通大学医学院附属仁济医院召开。该培训基地以前列腺扩开术为载体,立足国内外前列腺增生症的培训研究,通过国际合作和交流,探讨研究前列腺增生创新术式,为前列腺增生学术研究在学科,智库建设和人才培养上起到积极的作用。据悉,“经尿道柱状水囊前列腺扩开术”是我国自主研发,由北大医院郭应禄院士团队经过二十余年临床研究,基于对技术不断改进所完成的临床

Sci Rep:前列腺光选择性蒸发和钬激光去核治疗后生活质量研究

最近,有研究人员比较了120W高性能光选择性蒸发(PVP)系统和钬激光去核治疗(HoLEP)在良性前列腺增生(BPH)患者中的术后生活质量(QoL)的一系列长期变化,从而鉴定术后能够短期、中期和长期影响QoL改善的相关因素。研究包括了1193名患者,基线QoL指数≥2,且经历PVP的患者有439名,经历HoLEP的有754名。研究人员利用国际前列腺症状评分(I-PSS)、尿流量测定和血清PSA对2

Sci Rep:三次犹豫模糊集的Dice测量和对良性前列腺增生症状的初步评估

为了对一名患者进行良性前列腺增生(BPH)症状的初步评估,医生经常对患者进行临床询问,而患者的回应可能经常包括一些犹豫模糊和不确定的信息。然而,已经存在的BPH症状评估/诊断方法不能同时满足对患者犹豫和不确定信息的有效处理。更多的是,已经存在的评估方法可能会失去一些有用的信息(比如犹豫模糊信息),从而导致对患者病情的不合理或者不确定的评估/诊断。最近,有研究人员为了克服上述缺陷,首次引入了三次犹豫

Sci Rep:Pao Pereira提取物能够减弱小鼠中睾酮诱导的良性前列腺增生

良性前列腺增生(BPH)是老年人中最常见的泌尿系统疾病之一。Pao提取物是一种中草药制剂,来源于亚马逊热带雨林树木Pao Pereira(夹竹桃科)的树皮,该提取物被报道能够抑制前列腺癌细胞的增生。最近,有研究人员调查了Pao Pereira提取物在一个睾酮诱导的BPH小鼠模型中的治疗作用情况。研究发现,与注射睾酮溶剂的sham组相比,睾酮的注射能够诱导前列腺增大。BPH/Pao组与BPH/非那雄

BMJ:前列腺增生继发下尿路症状临床治疗方法比较研究

研究认为,前列腺动脉栓塞与电切治疗前列腺增生继发下尿路症状的临床疗效差异不显著,但栓塞对患者前列腺功能改善的效果劣于电切治疗,不良事件更少

Baidu
map
Baidu
map
Baidu
map